March 2016—Both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) halted ongoing first-line trials of idelalisib in combination with other agents due to an increased risk of serious adverse events including death, mostly due to infections.
This CME-certified case presentation contains an interactive video case with voting and commentary customized to each case option, along with downloadable slides to complement the interactive case. This educational activity provides physicians with guidance on the management of patients with chronic lymphocytic leukemia (CLL).
Susan O'Brien, MDUC Irvine Health
Chao Family Comprehensive Cancer Center
Orange, California, United States
This educational activity is specifically designed to meet the needs of practicing hematologists, oncologists and other healthcare professionals involved in the treatment of patients with CLL.
After successful completion of this educational activity, participants should be able to:
- Discuss recent clinical trial data regarding the safety and efficacy of novel therapies for the treatment of chronic lymphocytic leukemia (CLL)
- Employ best practices in the treatment of patients with CLL regarding treatment selection and integration of novel agents when appropriate
- Identify optimal treatment strategies for patients with poor-risk CLL
- Evaluate treatment options for elderly patients with CLL and potential strategies to improve efficacy and tolerability of therapy
- Discuss strategies to identify and manage treatment-related adverse events in patients with CLL to improve patient care
- Identify appropriate clinical trials in which to enroll patients with CLL
This activity is provided by prIME Oncology.
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
prIME Oncology designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This educational activity is supported by a grant from Gilead Sciences, Inc.
April 21, 2015
April 21, 2016